Detalles de la búsqueda
1.
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.
Cancer Immunol Immunother
; 68(5): 799-812, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30770959
2.
A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile.
Int J Cancer
; 137(2): 372-84, 2015 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25530186
3.
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.
BMC Cancer
; 14: 748, 2014 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-25288198
4.
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.
J Immunother Cancer
; 7(1): 38, 2019 02 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30736848
5.
Characterization of the ribonuclease activity on the skin surface.
Genet Vaccines Ther
; 4: 4, 2006 May 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-16732888
6.
Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy.
Oncoimmunology
; 5(12): e1249560, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-28123889
7.
Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas.
Genet Vaccines Ther
; 3: 6, 2005 Aug 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-16115316
8.
Co-transfection of messenger RNA and siRNA as a method to study the efficiency of siRNA.
Nucleosides Nucleotides Nucleic Acids
; 24(2): 147-52, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-15822620
9.
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study.
J Immunother Cancer
; 3: 26, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26082837
10.
A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines.
Hum Vaccin Immunother
; 9(10): 2263-76, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23921513
11.
Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients.
J Immunother
; 32(5): 498-507, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19609242
12.
Results of the first phase I/II clinical vaccination trial with direct injection of mRNA.
J Immunother
; 31(2): 180-8, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18481387
13.
Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA.
Eur J Immunol
; 36(10): 2807-16, 2006 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-17013976
14.
Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA.
Eur J Immunol
; 35(5): 1557-66, 2005 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-15832293
15.
Immunostimulating capacities of stabilized RNA molecules.
Eur J Immunol
; 34(2): 537-47, 2004 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-14768059
Resultados
1 -
15
de 15
1
Próxima >
>>